FDA Cardio-Renal Drugs Advisory Committee
Oct. 13 meeting will discuss broader indication for Squibb's Capoten (captopril) in congestive heart failure; and Merck's Vasotec (enalapril) and Prinivil (lisinopril) as second line treatment in conjunction with digitalis and diuretics. Meeting will be held at Lister Hill auditorium. Capoten is already approved for second-line treatment of congestive heart failure. Prinivil, a second-generation ACE inhibitor, has not been approved for either use. In 1986, Merck exchanged U.S. comarketing rights to lisinopril to Stuart, which will market the product under the brand name Zestril.
You may also be interested in...
In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”
Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.